 |
|
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi
Intest Res. 2017;15(3):395-401. Published online 2017 Jun 12 DOI: https://doi.org/10.5217/ir.2017.15.3.395
|
|
Citations to this article as recorded by
 Positive antiphospholipid antibodies and pulmonary embolism in a patient with adalimumab-induced lupus
Masaaki Uehara, Shinya Matsushita, Satsuki Aochi, Motohisa Yamamoto
Modern Rheumatology Case Reports.2023; 7(1): 68. CrossRef Hemorrhagic gastric ulcer in a patient with Behcet's disease successfully treated with infliximab
Shun Fujiwara, Ami Kawamoto, Maiko Motobayashi, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Eiko Saito, Toshimitsu Fujii, Masakazu Nagahori, Daisuke Kawata, Natsuka Umezawa, Tadashi Hosoya, Shinsuke Yasuda, Kazuo Ohtsuka, Ryuichi Okamoto
DEN Open.2023;[Epub] CrossRef Treatment Options in Pediatric Behçet’s Disease
Teresa Giani, Angela Flavia Luppino, Giovanna Ferrara
Pediatric Drugs.2023; 25(2): 165. CrossRef Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
Jae Hee Cheon, Hyun-Soo Kim, Dong Soo Han, Sung Kook Kim, Sung Jae Shin, Joo Sung Kim, Byong Duk Ye, Geun Am Song, YoungJa Lee, Youngdoe Kim, Yoosun Lee, Won Ho Kim
Gut and Liver.2023; 17(5): 777. CrossRef Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
BMC Gastroenterology.2023;[Epub] CrossRef The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis
Mengyuan Zhang, Jinjing Liu, Tingting Liu, Wei Han, Xiaoyin Bai, Gechong Ruan, Hong Lv, Huijun Shu, Yue Li, Ji Li, Bei Tan, Weiyang Zheng, Hui Xu, Wenjie Zheng, Hong Yang, Jiaming Qian
Journal of Gastroenterology and Hepatology.2022; 37(4): 608. CrossRef Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
Haruka Miyazaki, Daisuke Watanabe, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Namiko Hoshi, Makoto Ooi, Yuzo Kodama
BMC Gastroenterology.2022;[Epub] CrossRef New insights on multigenic autoinflammatory diseases
Petros Efthimiou, Olga Petryna, Priscila Nakasato, Apostolos Kontzias
Therapeutic Advances in Musculoskeletal Disease.2022; 14: 1759720X2211178. CrossRef Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis
Shukai Zhan, Caiguang Liu, Na Li, Tong Li, Zhenyi Tian, Min Zhao, Dongxuan Wu, Minhu Chen, Zhirong Zeng, Xiaojun Zhuang
Therapeutic Advances in Gastroenterology.2022; 15: 175628482211166. CrossRef Clinical Manifestations and Management of Pediatric Behçet’s Disease
Ya-Chiao Hu, Bor-Luen Chiang, Yao-Hsu Yang
Clinical Reviews in Allergy & Immunology.2021; 61(2): 171. CrossRef Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef Mucosal healing in intestinal Behçet's disease: A systematic review and meta‐analysis
Liang Gong, Yue Lun Zhang, Lu Xi Sun, Guo Rong Chen, Dong Wu
Journal of Digestive Diseases.2021; 22(2): 83. CrossRef Experimental Therapeutic Solutions for Behcet’s Disease
Burçin Cansu Bozca, Erkan Alpsoy
Journal of Experimental Pharmacology.2021; Volume 13: 127. CrossRef Advances in the Treatment of Behcet’s Disease
Fatma Alibaz-Oner, Haner Direskeneli
Current Rheumatology Reports.2021;[Epub] CrossRef Behçet Disease: An Update for Dermatologists
Erkan Alpsoy, Burcin Cansu Bozca, Asli Bilgic
American Journal of Clinical Dermatology.2021; 22(4): 477. CrossRef Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi
Intestinal Research.2021; 19(3): 301. CrossRef Juvenile-onset Behçet's syndrome and mimics
Clare E. Pain
Clinical Immunology.2020; 214: 108381. CrossRef Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
Yehyun Park, Jae Hee Cheon
Current Gastroenterology Reports.2020;[Epub] CrossRef An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Kader Cetin Gedik, Micol Romano, Roberta A. Berard, Erkan Demirkaya
Current Treatment Options in Rheumatology.2020; 6(2): 99. CrossRef Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone
Expert Opinion on Drug Safety.2020; 19(10): 1269. CrossRef The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions
Harutaka Kambayashi, Teppei Omori, Satomi Saito, Shun Murasugi, Hiroyuki Kashiwagi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
Internal Medicine.2020; 59(19): 2343. CrossRef Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
Medicine.2019; 98(9): e14624. CrossRef Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet’s disease
Naomi Sugimura, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Tomokatsu Miyaki, Taketo Suzuki, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki
Digestive and Liver Disease.2019; 51(7): 967. CrossRef Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Shingo Nakayamada, Kazuyoshi Saito, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki, Yoshiya Tanaka
Arthritis Research & Therapy.2019;[Epub] CrossRef Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan
Ya-Chiao Hu, Yao-Hsu Yang, Yu-Tsan Lin, Li-Chieh Wang, Hsin-Hui Yu, Jyh-Hong Lee, Bor-Luen Chiang
BMC Pediatrics.2019;[Epub] CrossRef Management of Behçet's disease
Fatma Alibaz-Oner, Amr H. Sawalha, Haner Direskeneli
Current Opinion in Rheumatology.2018; 30(3): 238. CrossRef Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef Gastrointestinal Involvement in Behçet Disease
Ibrahim Hatemi, Gulen Hatemi, Aykut Ferhat Çelik
Rheumatic Disease Clinics of North America.2018; 44(1): 45. CrossRef Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease
Jihye Park, Jae Hee Cheon
Gut and Liver.2018; 12(6): 623. CrossRef Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
Jihye Park, Jae Hee Cheon
Intestinal Research.2017; 15(3): 263. CrossRef
|